Found 24 clinical trials
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.
- 0 views
- 15 Oct, 2021
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.
- 0 views
- 15 Oct, 2021
- 1 location
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel (gem+nabP), that are routinely prescribed in combination for metastatic pancreatic cancer as part of their routine care.
- 0 views
- 15 Oct, 2021
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …
- 0 views
- 16 Feb, 2024
- 1 location
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
Giving NBTXR3 followed by radiation therapy may work better to treat locally advanced or borderline-resectable pancreatic cancer compared to radiation therapy alone.
- 0 views
- 16 Feb, 2024
- 1 location
Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.
A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients …
- 0 views
- 16 Feb, 2024
- 8 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Eligibility Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies. Also, children age 12-17 with a solid tumor (other than a muscle tumor) with no standard therapy options.
- 0 views
- 16 Feb, 2024
- 1 location
Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers RT-CAMSS Study
This trial tests new methods and materials for the real-time chemotherapy-associated side effects monitoring support system (RT-CAMSS) in patients with gastrointestinal cancers undergoing chemotherapy. RT-CAMSS is a monitoring support system that provides patients with evidence-based information and side-effect management and coping skills, emotional support and validation, and proactive care via …
- 0 views
- 16 Feb, 2024
- 1 location
Cohort Study of Pancreatic Cancer Risk
Mayo Clinic is part of a national Pancreatic Cancer Detection Consortium (PCDC)[1] which aims to establish a high-risk cohort with the goal of validating blood biomarkers (discovered/developed outside of this protocol) using the samples collected serially (annually) that predict or detect pancreatic cancer prior to clinical diagnosis.
- 0 views
- 16 Feb, 2024
- 1 location
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
- 0 views
- 16 Feb, 2024
- 1 location